Acadia Pharmaceuticals (ACAD) Receivables - Net (2016 - 2025)
Acadia Pharmaceuticals (ACAD) has 10 years of Receivables - Net data on record, last reported at $121.5 million in Q4 2025.
- For Q4 2025, Receivables - Net rose 23.01% year-over-year to $121.5 million; the TTM value through Dec 2025 reached $121.5 million, up 23.01%, while the annual FY2025 figure was $121.5 million, 23.01% up from the prior year.
- Receivables - Net reached $121.5 million in Q4 2025 per ACAD's latest filing, up from $115.8 million in the prior quarter.
- Across five years, Receivables - Net topped out at $121.5 million in Q4 2025 and bottomed at $51.4 million in Q2 2021.
- Average Receivables - Net over 5 years is $83.3 million, with a median of $87.3 million recorded in 2023.
- Peak YoY movement for Receivables - Net: fell 8.18% in 2022, then surged 66.51% in 2023.
- A 5-year view of Receivables - Net shows it stood at $64.4 million in 2021, then dropped by 3.37% to $62.2 million in 2022, then soared by 58.0% to $98.3 million in 2023, then grew by 0.48% to $98.7 million in 2024, then grew by 23.01% to $121.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $121.5 million in Q4 2025, $115.8 million in Q3 2025, and $107.5 million in Q2 2025.